BL
CNCR

BCWM LLC’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

BCWM LLC’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-577,414
Closed -$6.92M – 62
2023
Q1 		$6.92M Buy
577,414
+25,830
+5% +$352K 2.19% 21
2022
Q4 		$7.57M Buy
551,584
+191,713
+53% +$2.8M 2.49% 14
2022
Q3 		$5.27M Sell
359,871
-254,056
-41% -$4.1M 1.91% 22
2022
Q2 		$9.33M Buy
613,927
+120,647
+24% +$1.85M 3.18% 6
2022
Q1 		$8.88M Buy
493,280
+241,743
+96% +$4.59M 2.65% 14
2021
Q4 		$5.99M Sell
251,537
-80,138
-24% -$2.23M 1.76% 23
2021
Q3 		$10.1M Buy
331,675
+7,607
+2% +$230K 3% 5
2021
Q2 		$10.3M Buy
324,068
+8,192
+3% +$247K 3.05% 4
2021
Q1 		$9.45M Sell
315,876
-26,921
-8% -$876K 2.79% 8
2020
Q4 		$10.9M Buy
342,797
+7,991
+2% +$240K 3.24% 5
2020
Q3 		$9.19M Buy
334,806
+3,154
+1% +$84.3K 3.12% 3
2020
Q2 		$8.98M Buy
331,652
+287
+0.1% +$7.05K 3.22% 2
2020
Q1 		$6.47M Buy
331,365
+104,259
+46% +$2.25M 2.7% 6
2019
Q4 		$5.32M Buy
227,106
+5,570
+3% +$118K 1.9% 20
2019
Q3 		$4.16M Buy
221,536
+3,398
+2% +$69K 1.68% 30
2019
Q2 		$4.61M Buy
218,138
+6,629
+3% +$136K 1.84% 22
2019
Q1 		$4.45M Buy
211,509
+131,167
+163% +$2.75M 2% 18
2018
Q4 		$15.2M Sell
80,342
-100,914
-56% -$2.1M 0.72% 56
2018
Q3 		$4.5M Buy
181,256
+17,627
+11% +$433K 1.88% 21
2018
Q2 		$3.95M Buy
163,629
+4,676
+3% +$126K 1.73% 27
2018
Q1 		$4.62M Sell
158,953
-3,533
-2% -$100K 1.97% 15
2017
Q4 		$3.86M Sell
162,486
-302
-0.2% -$7.63K 1.58% 30
2017
Q3 		$4.41M Buy
162,788
+620
+0.4% +$15.1K 1.85% 19
2017
Q2 		$3.73M Buy
162,168
+11,665
+8% +$264K 1.66% 27
2017
Q1 		$3.66M Buy
150,503
+14,537
+11% +$334K 1.65% 25
2016
Q4 		$2.89M Buy
+135,966
New +$3.12M 1.34% 36

Other funds holding CNCR

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BCWM LLC's CNCR Position: Q2 2023 in Review

BCWM LLC sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2023, closing a stake of 577,414 shares — an estimated $6.92M sold.

BCWM LLC first reported a position in CNCR in Q4 2016 and held it in 26 quarters. The position peaked at $15.2M in Q4 2018. 14 funds tracked by Wall St. Rank hold CNCR as of Q2 2023.

  • BCWM LLC reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2023 after selling out during the quarter.
  • BCWM LLC sold 577,414 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2023, an estimated $6.92M.
  • BCWM LLC first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2016 and held it in 26 quarters.
  • BCWM LLC's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $15.2M in Q4 2018.
  • 14 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2023.

Based on BCWM LLC's 13F filing for Q2 2023, filed 14 Aug 2023.